Cargando…
Efficacy and safety of pemetrexed on recurrent primary central nervous system lymphomas in China: a prospective study
BACKGROUND: Pemetrexed, a new and novel agent for primary central nervous system lymphomas (PCNSLs), has shown to be efficient as a savage therapy for recurrent PCNSLs. However, more studies are needed. A prospective study was performed on 17 recurrent PCNSL patients with pemetrexed at Shandong Tumo...
Autores principales: | Sun, Yi, Wang, Yong, Han, Shaolong, Xing, Bo, Li, Hong, Zhu, Yufang, Zhou, Shizhen, Wang, Xiuhua, Xu, Jun, Tao, Rongjie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5440074/ https://www.ncbi.nlm.nih.gov/pubmed/28553124 http://dx.doi.org/10.2147/OTT.S134684 |
Ejemplares similares
-
Pemetrexed for Recurrent Primary Central Nervous System Lymphoma in the Elderly: Results of a Retrospective Study
por: Xiao, Jing, et al.
Publicado: (2022) -
Retracted: Pemetrexed for Recurrent Primary Central Nervous System Lymphoma in the Elderly: Results of a Retrospective Study
por: Healthcare Engineering, Journal of
Publicado: (2023) -
Pemetrexed Plus Lenalidomide for Relapsed/Refractory Primary Central Nervous System Lymphoma: A Prospective Single-Arm Phase II Study
por: Ma, Jingjing, et al.
Publicado: (2022) -
Apatinib Plus Temozolomide for Recurrent Glioblastoma: An Uncontrolled, Open-Label Study
por: Wang, Yong, et al.
Publicado: (2019) -
Efficacy and safety of pemetrexed and nedaplatin followed by pemetrexed maintenance therapy in advanced lung adenocarcinoma
por: Lin, Zhong, et al.
Publicado: (2017)